Table 2.

The risk of pancreatic cancer and pancreatic adenocarcinoma for all long-term proton pump inhibitor users in Sweden (defined as ≥ 180 days accumulated use), presented as standardized incidence rate ratios (SIRs) and 95% confidence intervals (CI)

	Person years	Total		Adenocarcinoma
		N (%)	SIRs (95% CI)	N (%)	SIRs (95% CI)
Total	3,828,553	1733	2.22 (2.12–2.32)	1394	2.26 (2.14–2.38)
Sex
Women	2,275,213	917	2.04 (1.91–2.17)	742	2.10 (1.95–2.26)
Men	1,553,340	816	2.46 (2.30–2.64)	652	2.46 (2.28–2.66)
Age
< 40 years	333,857	10	8.90 (4.26–16.37)	7	12.30 (4.93–25.34)
40–49 years	475,113	65	5.93 (4.58–7.56)	54	6.62 (4.97–8.63)
50–59 years	729,786	230	3.36 (2.94–3.82)	187	3.29 (2.84–3.80)
60–69 years	954,060	602	2.46 (2.26–2.66)	520	2.47 (2.27–2.70)
≥ 70 years	1,335,737	826	1.81 (1.69–1.94)	626	1.83 (1.69–1.98)
Indications of use
Gastro-esophageal reflux	979,793	409	2.06 (1.86–2.27)	331	2.01 (1.87–2.33)
Peptic ulcers	359,158	234	2.59 (2.27–2.94)	182	2.56 (2.20–2.96)
Gastroduodenitis	526,036	307	2.75 (2.45–3.08)	245	2.78 (2.44–3.15)
Helicobacter pylori infection/eradication	288,390	160	2.99 (2.54–3.49)	121	2.85 (2.37–3.41)
Long-term aspirin usea	497,202	222	1.55 (1.36–1.77)	173	1.56 (1.33–1.81)
Long-term NSAIDs usea	571,664	210	2.33 (2.03–2.67)	174	2.40 (2.06–2.79)
Diabetes mellitus drugs	164,936	152	3.76 (3.19–4.41)	118	3.68 (3.05–4.41)
Time since start PPIs
First year	979,007	689	4.35 (4.03–4.68)	589	4.62 (4.25–5.01)
1–3 years	2,340,030	414	1.28 (1.16–1.40)	331	1.25 (1.12–1.39)
3–5 years	1,159,914	362	1.40 (1.26–1.55)	286	1.40 (1.25–1.58)
> 5 years	747,495	268	1.57 (1.38–1.76)	188	1.45 (1.25–1.67)

NSAIDs non-steroidal anti-inflammatory drugs

^aNo other gastrointestinal indications recorded